As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

Early Data Suggests Superiority Against Pain Crises

 
• By Andrew McConaghie

While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.

ASH
The growth of blood cancer pipelines, as well as other hematological disorders, has made ASH a key congress • Source: ASH

More from Archive

More from Scrip